Biogen C.E.O. to Step Down Following Launch of Alzheimer’s Drug, Aduhelm
The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefits and serious safety risks.
The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefits and serious safety risks.
The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefits and serious safety risks.
The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefits and serious safety risks.
The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefits and serious safety risks.
The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefit and serious safety risks.
Officials cited data showing the new Alzheimer’s drug has serious safety risks and may not help patients.
The Alzheimer’s Association has pushed relentlessly to get broad access to Aduhelm, despite safety risks and uncertain evidence that it helps patients.
The agency’s accelerated approval program for certain drugs has come under intense scrutiny because some medicines stay on the market despite limited evidence that they […]
A drug to prevent preterm birth may provide the next test of the agency’s process for speedily getting drugs on the market, despite limited evidence […]
The narrow 50-46 decision underscored the divisions on both sides of the aisle over agency policies on opioids and abortion medications and his ties to […]
If the preliminary decision is finalized this spring, it would restrict coverage to patients in randomized clinical trials.
If the preliminary decision is finalized this spring, it would restrict coverage to patients in randomized clinical trials.
If the preliminary decision is finalized this spring, it would sharply limit the number of patients who use the expensive drug.
Medicare officials are trying to determine whether to cover Aduhelm, which the F.D.A. approved despite unclear evidence that it helps patients.
A higher Medicare premium in 2022 is just part of the puzzle of health care costs for older Americans. But there are ways to plan.
A higher Medicare premium in 2022 is just part of the puzzle of health care costs for older Americans. But there are ways to plan.
A higher Medicare premium in 2022 is just part of the puzzle of health care costs for older Americans. But there are ways to plan.
A higher Medicare premium in 2022 is just part of the puzzle of health care costs for older Americans. But there are ways to plan.
A higher Medicare premium in 2022 is just part of the puzzle of health care costs for older Americans. But there are ways to plan.
A group of Alzheimer’s experts and health advocates called on the F.D.A. to withdraw its approval of the drug, the latest of several setbacks for […]
A group of Alzheimer’s experts and health advocates called on the F.D.A. to withdraw its approval of the drug, the latest of several setbacks for […]
A group of Alzheimer’s experts and health advocates called on the F.D.A. to withdraw its approval of the drug, the latest of several setbacks for […]
A group of Alzheimer’s experts and health advocates called on the F.D.A. to withdraw its approval of the drug, the latest of several setbacks for […]
Newly published safety data shows that 41 percent of patients in key clinical trials of the Alzheimer’s drug experienced brain bleeding or swelling, though many […]
Newly published safety data shows that 41 percent of patients in key clinical trials of the Alzheimer’s drug experienced brain bleeding or swelling, though many […]
Newly published safety data shows that 41 percent of patients in key clinical trials of the Alzheimer’s drug experienced brain bleeding or swelling, though many […]
Newly published safety data shows that 41 percent of patients in key clinical trials of the Alzheimer’s drug experienced brain bleeding or swelling, though many […]
Newly published safety data shows that 41 percent of patients in key clinical trials of the Alzheimer’s drug experienced brain bleeding or swelling, though many […]
Newly published safety data shows that 41 percent of patients in key clinical trials of the Alzheimer’s drug experienced brain bleeding or swelling, though many […]
The drug, Aduhelm, has been mired in controversy since it was in approved in the United States in June.
The drug, Aduhelm, has been mired in controversy since it was in approved in the United States in June.
The drug, Aduhelm, has been mired in controversy since it was in approved in the United States in June.
The drug, Aduhelm, has been mired in controversy since it was in approved in the United States in June.
The drug, Aduhelm, brought in $300,000 in revenue in its first full three months of availability. The company expects the drug to generate minimal revenue […]
The drug, Aduhelm, brought in $300,000 in revenue in its first full three months of availability. The company expects the drug to generate minimal revenue […]
The agency approved Biogen’s Aduhelm “despite concerns raised by experts,” committee leaders said in a letter.
The agency approved Biogen’s Aduhelm “despite concerns raised by experts,” committee leaders said in a letter.
The agency approved Biogen’s Aduhelm “despite concerns raised by experts,” committee leaders said in a letter.
For an increasingly important set of drugs, Medicare has been driving up prices. It knows how to do better.
For an increasingly important set of drugs, Medicare has been driving up prices. It knows how to do better.
The drug from Biogen, called Aduhelm, is expected to generate billions in sales. It could also strain Medicare’s budget within a few years.
The drug from Biogen, called Aduhelm, is expected to generate billions in sales. It could also strain Medicare’s budget within a few years.
Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab.
Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab.
The major medical center’s rejection of the new Alzheimer’s drug is one of the starkest signs of concern over its effectiveness.
And how to learn more about the issue dividing school districts across the country.
The agency’s acting head said a review should look into whether any interactions between agency staff and the drug developer, Biogen, broke F.D.A. rules.
The approval of Aduhelm to treat Alzheimer’s disease has raised hope among older adults, but many doctors wonder if it is warranted.
The agency faced criticism for approving Aduhelm for all Alzheimer’s patients. Now it recommends that the drug be given only to those with mild symptoms.
The agency faced criticism for approving Aduhelm for all Alzheimer’s patients. The new label recommends that the drug be given only to patients with mild […]
The approval of Aduhelm to treat Alzheimer’s disease has raised hope among older adults, but many doctors wonder if it is warranted.
The F.D.A. shocked the world of medicine when it approved a much-debated drug for Alzheimer’s. What does the decision mean for patients and their families?
The F.D.A. shocked the world of medicine when it approved a much-debated drug for the disease. What does the decision mean for patients and their […]
Even those who supported the F.D.A.’s approval of the controversial new drug said authorizing it for anyone with Alzheimer’s disease was much too broad.
The Alzheimer’s treatment will cost $56,000 per patient, and millions may use it. The result: “crazy numbers” for Medicare.
The Alzheimer’s treatment will cost $56,000 per patient, and millions may use it. The result: “crazy numbers” for Medicare.
The F.D.A.’s approval of the Alzheimer’s drug aducanumab is inexplicable.
The F.D.A.’s approval of the Alzheimer’s drug aducanumab is inexplicable.
With the pandemic easing, the federal agency’s long-term agenda for drug approvals or new issues is languishing without a permanent commissioner.
The drug, Aduhelm, a monthly infusion priced at $56,000 per year, was approved this week despite weak evidence that it helps patients.
The drug, Aduhelm, a monthly infusion priced at $56,000 per year, was approved this week despite weak evidence that it helps patients.
Aducanumab, or Aduhelm, is the first new Alzheimer’s treatment in 18 years and the first to attack the disease process. But some experts say there’s […]
Copyright © 2024 | WordPress Theme by MH Themes